Monoclonal Antibody With Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
4/26/2013 9:58:10 AM
More...
|
Xencor Licenses Xtend™ Therapeutic Protein Half-life Extension Technology to CSL
4/16/2013 10:07:48 AM
More...
|
Xencor Initiates Phase 1b/2a Trial of XmAb® 5871 for Autoimmune Disease
2/13/2013 1:08:04 PM
More...
|
Xencor Initiates Phase 1b/2a Trial of XmAb� for Autoimmune Disease
2/13/2013 12:15:16 PM
More...
|
Xencor Receives Milestone Payment for Xtend™ Antibody
1/17/2013 9:44:25 AM
More...
|
Saber Bioscience Licenses Technology to Develop Optimized, Fully Human Antibodies
1/14/2013 12:04:14 PM
More...
|
MorphoSys AG and Xencor Report Clinical Data for MOR208/XmAb5574
11/5/2012 12:44:03 PM
More...
|
MorphoSys AG and Xencor Report Clinical Data for MOR208/XmAb5574
11/5/2012 9:14:24 AM
More...
|
MorphoSys AG and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial in CLL
5/22/2012 10:59:35 AM
More...
|
MorphoSys AG and Xencor Complete Enrollment in MOR208 (Xmab5574) Phase 1 Trial in CLL
5/22/2012 9:12:35 AM
More...
|
|